Latest Breaking News On - Johnm kirkwood - Page 1 : comparemela.com

GZ17-6.02 Eliminates Uveal Melanoma PDX Isolates

Study: GZ17-6.02 kills PDX isolates of uveal melanoma

A new research paper titled "GZ17-6.02 kills PDX isolates of uveal melanoma" has been published in Oncotarget.

Dr Kirkwood on the Evolving Treatment of Resected Melanoma

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.

Data From ESMO 2023 Further Define Treatment Paradigm in Advanced Melanoma

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.